Anthem Biosciences Limited
ANTHEM · ISIN: INE0CZ201020
Anthem Biosciences Limited is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE0CZ201020.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.05%), NIFTY LMC 250 TRI (0.11%), NIFTY MC 150 TRI (0.23%)
CHART
Anthem Biosciences Limited - growth of ₹100
Growth of ₹100 invested on 2025-07-25, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-3.31%
3M
+2.59%
6M
+9.22%
1Y
+15.31%
3Y CAGR
-
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Anthem Biosciences Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-08-26 | SHORT_SELL | 91 |
Frequently asked questions
What is Anthem Biosciences Limited's 1-year and 3-year return?
Anthem Biosciences Limited's 1-year price return is +15.31%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Anthem Biosciences Limited's latest financial performance?
Anthem Biosciences Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹2,002 Cr, with a TTM profit after tax of ₹576 Cr and an EBITDA margin of 39.39%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹13.63.
What is Anthem Biosciences Limited's quality score?
Anthem Biosciences Limited has a Punji quality score of 62.5 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Anthem Biosciences Limited's technical indicators show?
As of 2026-10-29, Anthem Biosciences Limited's RSI (14-day) is 43.15 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Anthem Biosciences Limited?
As of 2026-06-30, Anthem Biosciences Limited's shareholding is split across Promoter (71.4%), Public (28.6%), NonPromoterNonPublic (null%). Promoter holding of 71.4% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Anthem Biosciences Limited part of any major market index?
Yes - Anthem Biosciences Limited is a constituent of NIFTY 500 TRI (0.05% weight) and NIFTY LMC 250 TRI (0.11% weight) and NIFTY MC 150 TRI (0.23% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
Has Anthem Biosciences Limited seen any recent bulk or block deals?
Yes, as of 2026-08-26 - the most recent recorded deal was a SHORT_SELL on 2026-08-26 for 91 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns